DXCM is the ticker symbol for DEXCOM INC, a publicly traded Healthcare sector company listed on Nasdaq. 13F Pro tracks DXCM with AI-powered analysis, an AI quality score, SEC EDGAR financials, insider transactions, and institutional 13F holdings — all sourced directly from public SEC filings.

Is DXCM a good stock to buy?

13F Pro's AI ranking engine scores DXCM at 74.7/100, ranked #106 of 2,925 stocks on a composite quality score built from its SEC filings, covering profitability, growth, balance sheet strength, and free cash flow. The full AI verdict and bull/bear case for DXCM is available at https://13fpro.ai/company/DXCM. Not investment advice — review the underlying SEC filings before making any trade.

Where does 13F Pro source DXCM data?

All DEXCOM INC fundamentals and ownership data come directly from SEC EDGAR. DEXCOM INC files with the SEC under CIK 1093557. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

DEXCOM INC DXCM

NasdaqLarge CapHealthcare

13F Pro quality score

Rank #106 of 2,925TOP 5%

Why it scores 75 Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$1.31B

Quarter to Jun 30

Net income

$249.10M

Quarter to Jun 30

Free cash flow

$184.50M

Quarter to Jun 30

Operating margin

24.3%

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026

$27.05B total

BlackRock, Inc.

$2.71B+18.5%

VANGUARD CAPITAL MANAGEMENT LLC

$1.70B+0.8%

VANGUARD PORTFOLIO MANAGEMENT LLC

$1.32B+2.3%

STATE STREET CORP

$1.27B+13.8%

Invesco Ltd.

$1.03B+173.3%

BAILLIE GIFFORD & CO

$996.89M-5.1%

GEODE CAPITAL MANAGEMENT, LLC

$834.17M+0.6%

UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AME

$758.49M+15.6%

ALLIANCEBERNSTEIN L.P.

$734.35M-9.5%

WELLINGTON MANAGEMENT GROUP LLP

$574.33M-8.6%

ARROWSTREET CAPITAL, LIMITED PARTNERSHIP

$462.91M+170.1%

$462.57M--

$413.24M+35.0%

$382.99M-5.9%

$349.12M+7.8%

AMERIPRISE FINANCIAL INC

$324.71M+13.5%

FRANKLIN RESOURCES INC

$272.30M+1.1%

Castle Hook Partners LP

$260.67M+382.7%

JPMORGAN CHASE & CO

$255.54M+1.5%

GOLDMAN SACHS GROUP INC

$253.14M+23.5%

MASSACHUSETTS FINANCIAL SERVICES CO /MA/

$240.92M+84.1%

CIBC Bancorp USA Inc.

$232.97M-18.1%

CHARLES SCHWAB INVESTMENT MANAGEMENT INC

$231.63M+8.3%

NORTHERN TRUST CORP

$221.93M-3.8%

BANK OF AMERICA CORP /DE/

$220.03M+38.6%

See all 1,002 institutional holders →

What's Driving DXCM's Business? Latest 10-Q Breakdown

28/28 datapoints verified

AI-extracted from the 10-Q filed 2026-07-30 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Revenue rose 13% to $1.31B while gross margin expanded to 63.4% from 59.5%, lifting operating income 50% to $318.3M despite $45.6M of inventory reserve charges.

Biggest Revenue Drivers

Distributor$1,102.4M

Increased sales volume of disposable sensors from continued growth of the worldwide customer base

Direct$206.0M

Favorable revenue per customer primarily due to payor mix and utilization, partly offset by channel and product mix

Biggest Revenue Drivers

Total revenue: $1.31B+13% YoY

Distributor$1,102.4M

Increased sales volume of disposable sensors from continued growth of the worldwide customer base

Within Distributor

Distributor — United States$893.5M

Distributor — International$208.9M

Direct$206.0M

Favorable revenue per customer primarily due to payor mix and utilization, partly offset by channel and product mix

Within Direct

Direct — International$166.1M

Largest Expense Items

Cost of sales$478.4M+2% YoY

Increased primarily due to higher sales volumes; includes $45.6M of inventory reserve charges tied to planned G6 discontinuation

Selling, general and administrative$358.7M+9% YoY

$12.1M more advertising and marketing, $6.7M higher compensation, $6.3M higher facilities-related costs

Research and development$153.0M+3% YoY

Relatively flat due to the timing of project spend

Margins: Gross margin rose to 63.4% from 59.5% on higher volume, G7 15 Day benefits, manufacturing efficiencies and better fixed-cost absorption, offset by higher excess and obsolete inventory charges.

Watch Items from the Filing

Inventory reserve charges jumped to $45.6M from $8.8M a year ago, tied to planned discontinuation of G6 manufacturing; finished goods rose to $386.7M.
Six overlapping G6/G7 consumer class actions plus securities and derivative suits; company says it cannot reasonably estimate the ultimate outcome.
Operating cash flow of $269.2M fell 11% year over year even as net income rose 39%.
Repurchased 8.6 million shares for $600.0M under the new $1.00B 2026 program; management targets at least 50% of operating cash flow, net of capex, to buybacks.
Accrued rebates grew to $1,652.0M from $1,487.6M, and revenue was partly offset by rebate eligibility; $1.42B of open purchase commitments outstanding.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →

Key Metrics

Revenue

Q2 2026

EDGAR

Net Income

Q2 2026

EDGAR

EPS (Diluted)

Q2 2026

EDGAR

Operating Margin

Q2 2026

EDGAR

ROIC

Q2 2026

EDGAR

Free Cash Flow

Q2 2026

EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/DXCM

Earnings Per Share

13fpro.ai/company/DXCM

Loading ratio trend…

DEXCOM INC reported revenue, net income and margins by fiscal period, from SEC filings.
Period	Form	Revenue	Net income	Op. marginOperating margin
FY 2025	10-K	$4.7B	$836.3M	19.6%
FY 2024	10-K	$4.0B	$576.2M	14.9%
FY 2023	10-K	$3.6B	$541.5M	16.5%
FY 2022	10-K	$2.9B	$341.2M	13.4%
FY 2021	10-K	$2.4B	$216.9M	10.9%
FY 2020	10-K	$1.9B	$549.7M	15.5%

About DEXCOM INC (DXCM): stock profile, AI score and financials

DEXCOM INC (DXCM) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores DXCM at 74.7/100 on a composite quality score built from its SEC filings, placing it at rank #106 of 2,925 stocks — the top 5% of the AI-ranked universe. DXCM scores in the top quartile across balance sheet strength (92.5), profitability (84.1), free cash flow (82.3). Shareholder dilution risk is elevated at 29.6/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), DEXCOM INC reports quarterly revenue of $1.3B, net income of $249.1M, an operating margin of 24.3%. Top institutional holders of DXCM by reported 13-F value include BlackRock, VANGUARD CAPITAL MANAGEMENT, VANGUARD PORTFOLIO MANAGEMENT, based on the most recent SEC filings. DXCM trades on the Nasdaq exchange and files with the SEC under CIK 1093557. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate DXCM daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for DEXCOM INC directly from SEC EDGAR.

Financials through the period ended Jun 30, 2026SEC EDGAR: CIK 1093557 →

DEXCOM INC DXCM

Top Institutional Holders

What's Driving DXCM's Business? Latest 10-Q Breakdown

Biggest Revenue Drivers

Biggest Revenue Drivers

Largest Expense Items

Watch Items from the Filing

Key Metrics

Financial Trends

Revenue & Net Income

Earnings Per Share

DXCM key financials by period

DXCM insiders

Congress trading in DXCM

About DEXCOM INC (DXCM): stock profile, AI score and financials

DEXCOM INC DXCM

Top Institutional Holders

What's Driving DXCM's Business? Latest 10-Q Breakdown

Biggest Revenue Drivers

Key Metrics

Financial Trends

Revenue & Net Income

Earnings Per Share

DXCM key financials by period

Companies similar to DXCM

DXCM insiders

Congress trading in DXCM

About DEXCOM INC (DXCM): stock profile, AI score and financials